Toceranib phosphate for the treatment of dogs with high‐risk adrenal gland tumours: 16 cases (2019‐2023)
Journal of Small Animal Practice · 2025-06 · 66 (6) · 412-419
DOI: 10.1111/jsap.13840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Small Animal Practice, online erschienen am 20.02.2025. Verfasst von C Chalfon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centro Veterinario Torinese, Turin, Italy. Hauptthemen laut MEDLINE: Dog Diseases, Pyrroles, Indoles, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Objectives
The aims of this study were to evaluate the response rate, time to progression (TTP) and survival times of dogs with high‐risk adrenal gland tumours (ATs) treated with toceranib phosphate, in both macroscopic and microscopic setting, and to report the adverse event (AE) profiles. Materials and Methods Medical records of dogs diagnosed with a high‐risk adrenocortical carcinoma (ACC) or phaeochromocytoma (PCC), treated with toceranib, were retrospectively reviewed. High‐risk ATs were defined as inoperable and/or metastatic ATs or cortical tumours with high Utrecht score. Endpoints were response rate, TTP and overall progression‐free survival time (PFST). Adverse events were reported according to VCOG‐CTCAE.
Results
Sixteen dogs were included: 10 diagnosed with PCC and six with ACC. All dogs with ACC received adjuvant toceranib due to a high Utrecht score or metastatic disease, while all dogs with PCC were treated with toceranib in the macroscopic setting. A clinical benefit was detected in 80% of dogs with PCC: four achieved stable disease for a median TTP of 176.5 days, and two achieved partial response for 182 and >100 days, respectively. Median PFST for dogs with PCC was 112 days. Among dogs with ACC, 3 (50%) progressed and were euthanized after 237, 364 and 273 days; the remaining 3 (50%) dogs were alive and disease free 382, 508 and 583 days after starting toceranib. Overall, toceranib was well‐tolerated. Clinical Significance Toceranib may offer clinical benefit and improve outcome in dogs with high‐risk ATs in both the macroscopic and microscopic disease setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro Veterinario Torinese, Turin, Italy.
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy.
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
- Polo Oncologico Veterinario, AniCura Italy Holding S.r.l., Bologna, Italy.
ORCID-Profile: C Chalfon, L Marconato, A M Tardo, F Fracassi, F Del Baldo, R Finotello
Zitieren
APA
Chalfon, C., Marconato, L., Galac, S., Tardo, A. M., Zandvliet, M., Fracassi, F., Del Baldo, F., Ghisoni, G., Pisoni, L., & Finotello, R. (2025). Toceranib phosphate for the treatment of dogs with high‐risk adrenal gland tumours: 16 cases (2019‐2023). Journal of Small Animal Practice, 66(6), 412-419. https://doi.org/10.1111/jsap.13840
Vancouver
Chalfon C, Marconato L, Galac S, Tardo AM, Zandvliet M, Fracassi F, et al. Toceranib phosphate for the treatment of dogs with high‐risk adrenal gland tumours: 16 cases (2019‐2023). Journal of Small Animal Practice. 2025;66(6):412-419. doi:10.1111/jsap.13840
BibTeX
@article{Chalfon2025,
author = {Chalfon, C and Marconato, L and Galac, S and Tardo, A M and Zandvliet, M and Fracassi, F and Del Baldo, F and Ghisoni, G and Pisoni, L and Finotello, R},
title = {Toceranib phosphate for the treatment of dogs with high‐risk adrenal gland tumours: 16 cases (2019‐2023)},
journal = {Journal of Small Animal Practice},
year = {2025},
volume = {66},
number = {6},
pages = {412--419},
doi = {10.1111/jsap.13840}
}
EUVIMED